Last reviewed · How we verify

Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir — Competitive Intelligence Brief

Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir (Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI). Area: Infectious Disease / Virology.

marketed Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component) Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir (Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir) — St Stephens Aids Trust. These are antiretroviral drugs that inhibit HIV replication through different mechanisms: dolutegravir blocks integrase, efavirenz inhibits reverse transcriptase, and the combination tablet inhibits both reverse transcriptase and blocks viral entry.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir TARGET Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir St Stephens Aids Trust marketed Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) class)

  1. St Stephens Aids Trust · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir — Competitive Intelligence Brief. https://druglandscape.com/ci/dolutegravir-efavirenz-efavirenz-emtricitabine-tenofovir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: